Company valuation · Consumer Defensive
NUS: Hold with a $6.67 price target
Nu Skin Enterprises Inc. Borrowing is lower relative to earnings, but the latest quarter was loss-making.
- Model target · USD
- $6.67 For 2027-09-18
- Model rating
- Hold Reviewed 2026-09-18
- Reference weekly close
- $4.85 2026-09-11 · USD
Investment view
Borrowing is lower relative to earnings, but the latest quarter was loss-making.
Target and reference price
Target for 2027-09-18: $6.67 USD, +37.5% versus the $4.85 weekly close on 2026-09-11. Price return only; dividends, fees and tax excluded.
Price and earnings
Over 1 year (2025-09-12 to 2026-09-11), price changed -59.7% and trailing EPS changed -68.9%. A wider gap changes the earnings multiple; it does not establish fair value.
Supporting evidence
Net debt / EBITDA: 1.9× for NUS, against 4.3× across 11 comparable peers.
Risks to the case
Net income was -249.8m, compared with 21.1m in the same quarter last year. Amounts are in USD.
The latest quarterly operating margin was -18.5%, -26.5 percentage points from a year earlier. The full report separates sales growth from margin changes.
What to monitor
The latest quarterly margin changed -26.5 percentage points from a year earlier. Check sales volumes, pricing and unusual gains in the next filing.
Recheck the valuation gap alongside profitability and growth after new results. A discount alone does not establish value.
Compare the stock and the market fund over the same dates. Look for a change in relative performance as results arrive.
Valuation assumptions
Starting annual sales growth: -10%.
Long-term operating margin: 3.44%.
About this assessment
Review recorded on 2026-09-18. This is a dated summary of an automated company valuation. The full report includes the financial evidence, alternative scenarios and review history. Consult the latest report before using an earlier target. Automated model research, not personal investment advice. Targets depend on assumptions; returns are not guaranteed.